Insights from Consultant Kim Stuck: What’s New with Regulations, Quality Assurance, and the Future of the Industry

The patient-centered organization announced its 2025 plans for medical cannabis at the national level.

Aspergillus, a genus of mold that is abundant in our environment, has become a significant concern in the cannabis industry, particularly due to the health risks it poses to consumers. This mold, which thrives in various environments, including soil, decaying vegetation, and even in the air, is not inherently dangerous to healthy individuals. However, its presence in cannabis flowers, whether during cultivation, processing, or storage, can lead to severe health risks, especially for immunocompromised individuals.

The researchers point out that it is important for clinicians to ask about CBD use to better advise patients and prevent potential drug interactions.

Overall, the survey revealed that people with chronic pain supported policies expanding medical cannabis access more than physicians.

The study surveyed cannabis patients across the country on their use and perceptions of cannabis use during cancer treatment.

As discussions about the federal scheduling of cannabis continue, efforts by medical cannabis advocates are intensifying. One such advocate is Americans for Safe Access (ASA), a nonprofit organization founded by patients for patients. Since 2002, ASA has been championing the rights of medical cannabis patients and has recently launched new campaigns and strategies to refocus attention on patient needs. In this interview, Steph Sherer, founder and president of ASA, reflects on past successes in medical cannabis advocacy, shares her perspective on recent cannabis and hemp policymaking, and outlines the next steps for advancing a unified medical cannabis message on Capitol Hill—a message that could bring about the changes patients have long awaited.